Core Insights - Evolent Health, Inc. reported financial results for Q4 and the full year 2024, achieving revenue growth of 16.3% for the quarter and 30.1% for the year compared to 2023 [3][5] - The company maintained a 100% retention rate among its top customers, which account for over 90% of its 2024 revenue [2][3] - Adjusted EBITDA for Q4 was $22.6 million, with an adjusted EBITDA margin of 3.5%, while for the full year, adjusted EBITDA was $160.5 million with a margin of 6.3% [3][6] Financial Performance - Revenue for Q4 2024 was $646.5 million, and for the full year, it was $2.5547 billion [3][5] - The net loss attributable to common shareholders for Q4 was $30.6 million, resulting in a net loss margin of (4.7)%, while the full year net loss was $93.5 million with a margin of (3.7)% [3][5] - Adjusted income (loss) attributable to common shareholders for Q4 was $(2.5) million, and for the full year, it was $47.4 million [6][31] Business Outlook - For Q1 2025, the company expects revenue between $440 million and $470 million, and adjusted EBITDA between $31 million and $37 million [10] - For the full year 2025, revenue is projected to be approximately $2.06 billion to $2.11 billion, indicating a 15%-18% annual growth rate after adjusting for one-time contract changes [11] - The company anticipates an annual improvement of $115 million in net income and adjusted EBITDA due to recent contract amendments [3][11] Operational Metrics - Average lives on the Performance Suite platform increased to 7,145, while the Specialty Technology and Services Suite saw an increase to 75,161 [3][5] - The average PMPM fee for the Performance Suite was $21.32, and for the Specialty Technology and Services Suite, it was $0.37 [3][5] - The company added a primary care practice in the mid-Atlantic region to its Complex Care business, expanding its service offerings [8]

Core Viewpoint - Evolent Health, Inc. is enhancing its Board of Directors as part of its commitment to strong corporate governance and collaboration with shareholders, with Rick Jelinek set to become Chair and Brendan Springstubb appointed as a new independent director [1][2][3]. Board Changes - Rick Jelinek will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott, who has served since 2022 [2][5]. - Brendan Springstubb joins the Board as an independent director, bringing over 20 years of experience in investing in healthcare companies and expertise in strategy and investor communications [3][6]. Board Refreshment Efforts - The Board plans to refresh an independent director seat before the 2025 Annual Meeting, continuing a search process overseen by the Nominating and Governance Committee [4]. - Evolent has added five new independent directors to its Board in the past three years, reflecting ongoing efforts to enhance governance [4]. Leadership Insights - Cheryl Scott emphasized that the rotation of the Chair role and continued Board refreshment align with best practices in corporate governance [5]. - Glenn W. Welling, a significant shareholder, expressed confidence in Springstubb's ability to advocate for shareholders and highlighted Evolent's strong competitive position [5]. - CEO Seth Blackley noted the importance of the Board's skills and experience in creating value for stakeholders [5].

Core Points - Evolent Health, Inc. will release its fourth quarter 2024 financial results on February 20, 2025, after market close, followed by a conference call at 5 p.m. ET [1] - The company will participate in several upcoming investor conferences, including the Cowen 45th Annual Health Care Conference on March 4, 2025, the Oppenheimer 35th Annual Health Care MedTech and Services Conference on March 17, 2025, and the KeyBanc Annual Health Care Forum on March 19, 2025 [6] Company Overview - Evolent specializes in improving health outcomes for individuals with complex conditions through solutions that simplify and make healthcare more affordable [4] - The company serves a national base of leading payers and providers and is recognized as a top workplace in the healthcare sector [4]

Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chi ...

Lately, I’ve found myself in the peculiar role of covering stocks that have seen meteoric gains—those big, showy 100%-plus jumpers that have been on a tear, like IonQ ( IONQ ) and Applied Optoelectronics (The mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companies, offering the Seeking Alpha investor compelling po ...

evolent 1 Confidential – Do Not Distribute Evolent Health, Inc. Third Quarter 2024 Results November 7, 2024 CONTACT: Seth R. Frank Evolent Investor Relations sfrank@evolent.com Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, inclu ...

Core Insights - Evolent Health reported $621.4 million in revenue for Q3 2024, a year-over-year increase of 21.6%, but fell short of the Zacks Consensus Estimate of $625.58 million by -0.67% [1] - The company’s EPS for the quarter was $0.04, a significant decline from $0.30 a year ago, resulting in an EPS surprise of -86.67% compared to the consensus estimate of $0.30 [1] Revenue and Earnings Performance - Total revenue by product type for the Performance Suite was $435.10 million, compared to an estimate of $441.93 million, reflecting a year-over-year increase of +34.4% [3] - Total revenue for Cases was $41.43 million, below the estimated $43.18 million, with a year-over-year increase of +10.9% [3] - Administrative Services generated $59.40 million, slightly above the estimate of $58.87 million, but showed a year-over-year decline of -13.6% [3] - Specialty Technology and Services Suite revenue was $85.47 million, exceeding the estimate of $81.94 million, with a year-over-year increase of +5.2% [3] Key Metrics Analysis - Average PMPM Fees for the Performance Suite were $20.97, below the estimate of $21.43 [3] - Average Lives on Platform for Cases was 13 thousand, lower than the estimated 15.1 thousand [3] - Average PMPM Fees for Cases was $3,113, significantly higher than the estimated $2,859.51 [3] - Average Lives on Platform for Administrative Services was 1.26 million, slightly below the estimate of 1.27 million [3] Stock Performance - Evolent Health shares have returned -8.3% over the past month, contrasting with the Zacks S&P 500 composite's +4.9% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [4]

Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -86.67%. A quarter ago, it was expected that this health care software and consulting services provider would post earnings of $0.21 per share when it actually produced earnings of $0.30, delivering a surprise of 42. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVH New York Stock Exchange (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Revenue Performance - Revenue for Q3 2024 was $621.4 million, an increase of $110.4 million or 21.6% compared to Q3 2023[1] - Revenue for the three months ended September 30, 2024, was $621,401 thousand, a 21.6% increase from $511,015 thousand in the same period of 2023[25] - For Q4 2024, revenue is expected to be between $642.0 million and $667.0 million, with Adjusted EBITDA projected between $22.0 million and $37.0 million[12] - Full year 2024 revenue guidance is approximately $2.55 billion to $2.575 billion, with Adjusted EBITDA expected to be between $160.0 million and $175.0 million[13] Profitability and Loss - Net loss attributable to common shareholders was $(31.2) million, with a net loss margin of (5.0)%, an improvement from (6.5)% in Q3 2023[4] - The net loss attributable to common shareholders for the three months ended September 30, 2024, was $(31,231) thousand, compared to a net loss of $(33,196) thousand for the same period in 2023, reflecting an improvement[47] - The company reported a basic and diluted loss per common share of $(0.27) for the three months ended September 30, 2024, compared to $(0.30) in the same period of 2023[25] - Net loss before preferred dividends decreased to $38,821 thousand in September 2024 from $79,629 thousand in September 2023, representing a 51% improvement[28] - The company experienced a loss before income taxes of $(23,756) thousand for the three months ended September 30, 2024, an improvement from $(30,874) thousand in the same period of 2023[25] Adjusted EBITDA - Adjusted EBITDA for the quarter was $31.8 million, resulting in an Adjusted EBITDA margin of 5.1%, down from 9.5% in the same quarter last year[4] - The adjusted EBITDA for the three months ended September 30, 2024, was $31,801 thousand, with an adjusted EBITDA margin of 5.1%, down from $48,714 thousand and 9.5% in the prior year[47] - The company continues to expect average annual revenue growth in excess of 15% and average Adjusted EBITDA growth of 20% on a long-term basis[14] - Adjusted EBITDA margin is expected to provide further insight into operational performance compared to revenues over time, as management focuses on long-term operational costs[39] Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $637,669 thousand, compared to $528,953 thousand in the prior year, reflecting a 20.6% increase[25] - Adjusted cost of revenue for the three months ended September 30, 2024, was $539,591 thousand, up from $386,534 thousand in the same period of 2023, reflecting a 39% increase[44] - Total selling, general, and administrative expenses for the nine months ended September 30, 2024, were $215,349 thousand, down from $276,682 thousand in the same period of 2023[45] Cash and Liquidity - Cash and cash equivalents decreased to $96,583 thousand as of September 30, 2024, down from $192,825 thousand at the end of 2023[26] - Total current liabilities decreased to $523,683 thousand as of September 30, 2024, from $674,242 thousand at the end of 2023, indicating improved liquidity[26] - Cash and cash equivalents and restricted cash decreased to $127,851 thousand as of the end of September 2024 from $224,498 thousand at the end of September 2023, a decline of 43%[29] - Net cash provided by operating activities was $44,996 thousand for the nine months ended September 30, 2024, compared to $53,201 thousand for the same period in 2023[28] - The net cash used in investing activities was $43,002 thousand for the nine months ended September 30, 2024, compared to $409,492 thousand in the same period of 2023, showing a significant reduction[28] Contracts and Growth - Evolent announced six new contract agreements in Q3 2024, the highest number in the company's history, including a significant oncology Performance Suite agreement[6] - Evolent Health anticipates continued expansion and new partner additions, indicating a focus on growth despite current market dynamics[52] Risks and Challenges - The company faces risks related to the integration of acquisitions and maintaining profitability under performance-based contracts, which could impact future financial results[53] - The company faces risks related to the ability to contain health care costs and maintain adequate reserves for policy benefits[54] - There is a dependency on key personnel, impacting the ability to attract and retain talent[54] - The company has obligations to make material payments to pre-IPO investors for future tax benefits[54] - The company’s debt following the NIA acquisition raises concerns about meeting obligations[54] - There are potential volatility risks for the Class A common stock price, especially if a substantial number of shares are sold[54] - The company does not intend to pay cash dividends on its Class A common stock[54] - Risks related to legal proceedings and the safeguarding of confidential data may impact operations[54] - The company relies on third-party vendors for technology platform maintenance, which poses operational risks[54] - The conditional conversion features of the 2025 and 2029 Notes may adversely affect financial condition[54] - The company operates in a rapidly changing and competitive environment, with new risk factors emerging[55]